Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor

被引：0
|
作者：
Simon J. B. Aylwin
Istvan Bodi
Ronald Beaney
机构：
[1] King’s College Hospital,Department of Endocrinology
[2] King’s College Hospital,Department of Clinical Neuropathology
[3] Guy’s & St Thomas’ Hospital Cancer Centre,Department of Neuro
来源：
Pituitary | 2016年 / 19卷
关键词：
Vemurafenib; Craniopharyngioma; Prolactinoma; BRAF Inhibitor; BRAF V600E Mutation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：544 / 546
页数：2
相关论文
共 50 条
  • [11] Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy
    Brastianos, Priscilla K.
    Shankar, Ganesh M.
    Gill, Corey M.
    Taylor-Weiner, Amaro
    Nayyar, Naema
    Panka, David J.
    Sullivan, Ryan J.
    Frederick, Dennie T.
    Abedalthagafi, Malak
    Jones, Pamela S.
    Dunn, Ian F.
    Nahed, Brian V.
    Romero, Javier M.
    Louis, David N.
    Getz, Gad
    Cahill, Daniel P.
    Santagata, Sandro
    Curry, William T., Jr.
    Barker, Fred G., II
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2016, 108 (02):
  • [12] Papillary Craniopharyngioma in a Young Child: The Importance of BRAF Mutational Testing
    Magaki, Shino
    Raghavan, Ravi
    Minasian, Tanya
    De Los Reyes, Kenneth
    Kelly, Thomas
    Farzin-Gohar, Shadi
    Deisch, Jeremy K.
    CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 2020, 47 (01) : 148 - 150
  • [13] BRAF V600E mutations in papillary craniopharyngioma
    Brastianos, Priscilla K.
    Santagata, Sandro
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2016, 174 (04) : R139 - R144
  • [14] Vemurafenib for the treatment of BRAF mutant metastatic melanoma
    Martin-Liberal, Juan
    Larkin, James
    FUTURE ONCOLOGY, 2015, 11 (04) : 579 - 589
  • [15] Initial Presentation of Papillary Craniopharyngioma with BRAF Mutation Treated with Adjuvant Chemotherapy
    Gopal, Mangala
    Thakur, Gaurav
    Puduvalli, Vinaykumar
    NEUROLOGY, 2020, 94 (15)
  • [16] Treating Metastatic Melanoma With the BRAF Inhibitor Vemurafenib and Mechanisms of Resistance
    Chapman, P.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S24 - S24
  • [17] Update on Neoadjuvant and Adjuvant BRAF Inhibitors in Papillary Craniopharyngioma: A Systematic Review
    Cossu, Giulia
    Ramsay, Daniele S. C.
    Daniel, Roy T.
    El Cadhi, Ahmed
    Kerherve, Luc
    Morlaix, Edouard
    Houidi, Sayda A.
    Millot-Piccoli, Clement
    Chapon, Renan
    Van, Tuan Le
    Cao, Catherine
    Farah, Walid
    Lleu, Maxime
    Baland, Olivier
    Beaurain, Jacques
    Petit, Jean Michel
    Lemogne, Brivael
    Messerer, Mahmoud
    Berhouma, Moncef
    CANCERS, 2024, 16 (20)
  • [18] Abrupt development of Dupuytren's contractures with the BRAF inhibitor vemurafenib
    Couderc, Marion
    Soubrier, Martin
    JOINT BONE SPINE, 2014, 81 (04) : 373 - 374
  • [19] Acute Renal Failure Associated With the New BRAF Inhibitor Vemurafenib
    Launay-Vacher, Vincent
    Zimner-Rapuch, Sarah
    Poulalhon, Nicolas
    Fraisse, Thibault
    Garrigue, Valerie
    Gosselin, Morgane
    Amet, Sabine
    Janus, Nicolas
    Deray, Gilbert
    CANCER, 2014, 120 (14) : 2158 - 2163
  • [20] Immune reconstitution in patients with classical hairy cell leukemia during treatment with the BRAF inhibitor vemurafenib
    Konrat, J.
    Roiss, M.
    Rosler, W.
    Meier-Abt, F.
    Widmer, C. C.
    Balabanov, S.
    Manz, M. G.
    Zenz, T.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 38 - 39
12345